Cyclosporine in transplantation - A history of converging timelines

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 4, 2011, Pages 493-504

  Colombo, Delia ^a   Ammirati, E ^b,c  

^a Luigi Marchesi Hospital   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cyclosporine; History of drugs; Immunosuppressant agents; NFAT; Transplantation

Indexed keywords

AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; BASILIXIMAB; BOSENTAN; CARBAMAZEPINE; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DACLIZUMAB; DILTIAZEM; EVEROLIMUS; FLUCONAZOLE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MACROLIDE; METHOTREXATE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; OXCARBAZEPINE; PHENYTOIN; PREDNISOLONE; RAPAMYCIN; RIFAMPICIN; STEROID; SULFINPYRAZONE; TACROLIMUS; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ADJUVANT ARTHRITIS; ALLERGIC ENCEPHALOMYELITIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BACTERIAL INFECTION; BEHCET DISEASE; BIRTH DEFECT; BONE MARROW TOXICITY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DYSLIPIDEMIA; FETUS MALFORMATION; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEADACHE; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; LIVER FUNCTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MUSCLE CRAMP; MYALGIA; MYCOSIS; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PARASITOSIS; PARESTHESIA; PEMPHIGUS VULGARIS; PREGNANCY; PSORIASIS; PYODERMA GANGRENOSUM; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; TREMOR; UREA BLOOD LEVEL; UVEITIS; VIRUS INFECTION; VOMITING;

ANIMALS; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PREGNANCY;

EID: 84856022812     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 2002; 114:433-37. (Pubitemid 34764233)
2. Borel JF. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology 1976; 31:631-41.
3. Borel JF, Feurer C, Magnee C, Stahelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977; 32:1017-25. (Pubitemid 8120594)
4. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434:658-62. (Pubitemid 40488559)
5. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T--lymphocyte activation. Nature 1992; 357:695-97.
6. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324:277-84.
7. Edwards BD, Bhatnagar D, Mackness MI, Gokal R, Ballardie FW, Chalmers RJ, Durrington PN. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Qjm 1995; 88:109-13.
8. Calne RY, White DJ, Rolles K, Smith DP, Herbertson BM. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1978; 1:1183-85. (Pubitemid 8351729)
9. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2:1033-36. (Pubitemid 10213970)
10. Starzl TE, Klintmalm GB, Weil R, 3rd, et al. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981; 153:486-94. (Pubitemid 11007294)
11. Calne RY. Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 1987; 2:506-7. (Pubitemid 17126756)
12. Beveridge T, Calne RY. Cyclosporine (Sandimmun) in cadaveric renal transplantation. Ten- year follow-up of a multicenter trial. European Multicentre Trial Group. Transplantation 1995; 59:1568-70.
13. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309:809-15.
14. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schroter GP. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 1981; 305:266-69. (Pubitemid 11087372)
15. Powles RL, Barrett AJ, Clink H, Kay HE, Sloane J, McElwain TJ. Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 1978; 2:1327-31. (Pubitemid 9078431)
16. Oyer PE, Stinson EB, Reitz BA, Bieber CP, Jamieson SW, Shumway NE. Cardiac transplantation: 1980. Transplant Proc 1981; 13:199-206.
17. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967; 41:1271-74.
18. Caves PK, Stinson EB, Billingham M, Shumway NE. Percutaneous transvenous endomyocardial biopsy in human heart recipients. Experience with a new technique. Ann Thorac Surg 1973; 16:325-36.
19. Jamieson SW, Burton NA, Bieber CP, Reitz BA, Oyer PE, Stinson EB, Shumway NE. Survival of cardiac allografts in rats treated with cyclosporin A. Surg Forum 1979; 30:289-91. (Pubitemid 10144815)
20. Jamieson SW, Burton NA, Bieber CP, Reitz BA, Oyer PE, Stinson EB, Shumway NE. Cardiac-allograft survival in primates treated with cyclosporin A. Lancet 1979; 1:545. (Pubitemid 9130919)
21. Robbins RC, Barlow CW, Oyer PE, et al. Thirty years of cardiac transplantation at Stanford university. J Thorac Cardiovasc Surg 1999; 117:939-51. (Pubitemid 29210778)
22. Crespo-Leiro MG. Calcineurin inhibitors in heart transplantation. Transplant Proc 2005; 37:4018-20. (Pubitemid 43015241)
23. Reitz BA, Bieber CP, Raney AA, Pennock JL, Jamieson SW, Oyer PE, Stinson EB. Orthotopic heart and combined heart and lung transplantation with cyclosporin-A immune suppression. Transplant Proc 1981; 13:393-96.
24. Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine-results at 24 months after transplantation. Transplantation 2001; 71:70-78. (Pubitemid 32105781)
25. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004; 36:378S-91S. (Pubitemid 38373896)
26. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of denovo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377:837-47.
27. Sanchez-Lazaro IJ, Almenar-Bonet L, Martinez-Dolz L, et al. Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. Transplant Proc 2010; 42:3199-200.
28. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-58. (Pubitemid 37025404)
29. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694-700. (Pubitemid 39453021)
30. Liptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006; 2:398-404. (Pubitemid 44034190)
31. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25:434-39.
32. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2010; 65-85.
33. Armenti VT, Moritz MJ, Davison JM. Parenthood posttransplantation: 50 years later. Transplantation 2008; 85:1389-90.
34. Armenti VT, Constantinescu S, Moritz MJ, Davison JM. Pregnancy after transplantation. Transplant Rev (Orlando) 2008; 22:223-40.
35. Grimer M. The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors. Nephrology (Carlton) 2007; 12(S):S98-S105.
36. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359:473-81.
37. Cour M, Loufouat J, Paillard M, Augeul L, Goudable J, Ovize M, Argaud L. Inhibition of mitochondrial permeability transition to prevent the post-cardiac arrest syndrome: a pre- clinical study. Eur Heart J 2010; 32:226-35.
38. Duchen MR, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993; 27:1790-94. (Pubitemid 23337871)
39. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005; 280:18558-61. (Pubitemid 41379552)
40. Elrod JW, Wong R, Mishra S, et al. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest 2010; 120:3680-87.